Stories

A major review of global smoking cessation research adds further evidence that nicotine-containing e-cigarettes can help smokers quit more effectively than several commonly used methods, including patches, gum, non-nicotine e-cigarettes and behavioural support alone. The strongest reviews found more consistent benefits for nicotine e-cigarettes, while lower-quality studies produced less certain results. Researchers also highlight remaining evidence gaps, including limited comparisons with some pharmacological treatments and uncertainty around long-term safety outcomes. The findings reinforce the importance of assessing smoking cessation tools through relative risk, real-world effectiveness and the goal of reducing exposure to combustible tobacco.

France’s move to ban ZYN nicotine pouches is intensifying debate over whether prohibition-based regulation can deliver effective public health outcomes. Critics argue that severe penalties for smoke-free nicotine products risk creating a disproportionate framework in which lower-risk alternatives are treated more harshly than combustible cigarettes. The decision raises wider concerns about consumer access, illicit markets and the consistency of nicotine policy across Europe. Questions remain over whether such measures will reduce nicotine use overall or make it harder for adult smokers to move away from the most harmful forms of tobacco.

Alaska’s decision to tax vaping products and raise the legal tobacco purchase age to 21 is adding to wider debate over nicotine regulation in the United States. Supporters of the measure frame it as a youth prevention policy, while critics warn that higher costs for reduced-risk alternatives may discourage adult smokers from switching away from combustible cigarettes. The legislation highlights ongoing tensions between taxation, age restrictions, public health messaging and tobacco harm reduction. Questions remain over whether policies aimed at reducing nicotine use broadly can avoid unintended consequences for smokers seeking lower-risk options.

Declines in youth vaping in the United States appear to be increasingly at odds with perceptions of an escalating school-based crisis. Official survey data indicate substantial reductions in teen vaping in recent years, while school-level concern remains high due to increased detection, heightened awareness and broader media attention. Researchers and harm reduction advocates warn that this gap between evidence and perception may contribute to policies that restrict adult access to lower-risk nicotine products. The debate highlights the importance of interpreting youth vaping trends carefully, distinguishing between visibility and prevalence, and grounding nicotine regulation in reliable population-level data.

Longstanding public health narratives around nicotine are facing renewed scrutiny as tobacco harm reduction challenges older assumptions shaped by the cigarette era. Critics argue that framing nicotine itself as the central danger has contributed to public misunderstanding of reduced-risk products such as vapes, where the main issue is not combustion but the delivery of nicotine without smoke. The discussion raises concerns that fear-based language, including terms such as “epidemic” and misleading comparisons with illicit drugs, may distort risk perception and weaken evidence-based policy. Broader questions remain over whether tobacco control can adapt to scientific evidence on relative risk while maintaining credible public health communication.

Criticism of the WHO’s tobacco control strategy is increasingly centred on concerns that global policy is failing to recognise evidence from countries that have reduced smoking through harm reduction approaches. Advocates argue that lower-risk nicotine products, including vapes, snus and nicotine pouches, can play an important role in reducing exposure to the harms caused by combustible tobacco. The debate highlights ongoing tensions between abstinence-focused regulation and policies based on relative risk, consumer behaviour and real-world public health outcomes. Questions continue to grow over whether international tobacco control frameworks are adapting quickly enough to innovation, scientific evidence and declining smoking rates in countries that have embraced safer alternatives.

Clinical research into psilocybin-assisted therapy is adding to growing interest in psychedelic compounds as potential treatments for depression. A recent randomised trial found that a single dose of psilocybin, combined with psychotherapy, was associated with rapid improvements in depressive symptoms, with some effects lasting for several months. Researchers note, however, that the long-term benefits remain uncertain and that repeated or maintenance treatment may be needed to prevent relapse. The findings contribute to broader scientific debate over how psychedelic therapies should be studied, regulated, and integrated into mental health care.

Sweden has become the first European country to reach the smoke-free benchmark, with daily smoking falling below 5% of the population. The country’s long-term decline in cigarette use is increasingly being examined in relation to access to non-combustible nicotine products, including snus and nicotine pouches. Public health researchers continue to debate how Sweden’s experience should inform wider tobacco control strategies, particularly in countries where smoking prevalence remains significantly higher. The milestone reinforces the importance of distinguishing between nicotine use and the harms caused by tobacco combustion when designing evidence-based regulation.

Panama’s constitutional ruling on vaping adds to growing international debate over prohibition, consumer rights, and tobacco harm reduction policy. The decision raises questions about whether outright bans on lower-risk nicotine products are compatible with evidence-based public health objectives, particularly when combustible cigarettes remain legally available. Harm reduction advocates argue that regulated access to non-combustible alternatives may offer a more proportionate approach for adult smokers seeking to reduce their health risks. The case highlights wider tensions between restrictive nicotine regulation, constitutional principles, and strategies aimed at reducing smoking-related disease and mortality.

Research on third-hand exposure from vaping is adding new complexity to debates about nicotine product risk, toxicology, and public health communication. While animal models can provide useful insight into possible biological effects, researchers caution that findings must be interpreted carefully when assessing real-world human exposure. The debate highlights the importance of distinguishing between potential hazards observed under experimental conditions and actual population-level risk compared with cigarette smoke. It also reinforces the need for proportionate scientific communication that recognises uncertainty without obscuring the substantial risk differences between combustible and non-combustible nicotine products.